Unlock instant, AI-driven research and patent intelligence for your innovation.

Modified hepatitis c virus proteins

A kind of technology of hepatitis C virus and composition, applied in the direction of virus, virus peptide, immunoglobulin, etc.

Active Publication Date: 2013-10-16
THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently available treatments are limited to administration of ribavirin and pegylated interferon, which exhibit limited efficacy of 40-80% and cause severe side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified hepatitis c virus proteins
  • Modified hepatitis c virus proteins
  • Modified hepatitis c virus proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0283] Example 1: Single cysteine ​​disulfide bond substitution mutation in the context of co-expression of full-length E2 glycoprotein and E1

[0284] As proposed by Krey et al., 2010 (ibid.), the assignment of disulfide bonds in the domain structure of E2, such as figure 1 And shown in Table 2. In the context of E1E2 derived from genotype 1a isolate H77c in HCVpp, the effect of replacing cysteine ​​alone with alanine on E2 folding and function was evaluated. The substitution of Cys to Ala abolished the ability of HCVpp to infect Huh7 liver cancer cells, indicating that the 9 disulfide bonds of E2 are critical for cell entry ( figure 2 A). Western blot analysis of transfected cell lysates with MAb H52 (for E2) and MAb A4 (for E1) showed that E1 and E2 were expressed at wild-type levels ( figure 2 B). However, in the biosynthesis-labeled HCVpp immunoprecipitation, the use of conformation-dependent E2-specific MAb, H53 indicates that the mutation has caused defects in the glyco...

Embodiment 2

[0288] Example 2: Simultaneous mutagenesis of cysteine ​​pairs involved in disulfide bond formation

[0289] Cys-to-Ala scanning of HIV envelope glycoprotein gp120 / gp41 complex shows that cysteine ​​mutation alone is not conducive to the folding of functional protein, while Ala is substituted in 2 of the 10 disulfide bonds Both folding and function are saved (van Anken et al., Mol Biol Cell 19: 4298-309, 2008). In order to reduce the tendency of protein mismatch due to the presence of unpaired cysteine, Ala-substitution of each disulfide bond pair is performed at the same time. For the double Cys-to-Ala mutant, the intracellular expression and polyprotein processing of E1 and E2 were confirmed by Western blotting ( image 3 A), however, lacks HCVpp entry activity (data not shown). For C452A / C459A (domain II), C581A / C585A and C652A / C677A (domain III), the incorporation of H53-reactive E2 into HCVpp was observed, which did not form a heterodimer with E1 ( image 3 A). In these 3 ...

Embodiment 3

[0290] Example 3: The truncated E2 glycoprotein (E2 661 -his) single cysteine ​​and pairwise disulfide bond substitution mutations

[0291] Next, in the receptor binding domain of E2 (residues 384-661, E2 661 -His) to evaluate the impact of the Cys-to-Ala mutation in the context of E2, which is independent of the E1 folding, retains the three domain structures described by Krey et al., 2010 (supra), and retains the CD81 and SRB1 binding function. All mutants were secreted from transfected 293T cells at the wild-type level, as shown by the immunoprecipitation of the metabolically labeled protein through the C-terminal 6-His tag and anti-His antibody ( Figure 4 A, upper block). E2 661 -His mutants except for one MAb H53-reactivity attribute mostly reflects the observed reactivity attributes of the corresponding E1E2 mutant ( Figure 4 A, blocks 2 and 3, see figure 2 B). Therefore, the Cys residues necessary for H53 reactivity include C494, C508 (DII), C552, C564 (DI), C607 and C6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof. A method of producing a composition comprising at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70% monomelic HCV E2 polypeptide, the method comprising expressing a polypeptide in a host cell and isolating the expressed product, wherein the polypeptide is an HCV E2 polypeptide including a receptor binding variant, and wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597.

Description

Technical field [0001] The present invention relates to modified hepatitis C virus (HCV) E2 protein and methods for preparing and using it. Background technique [0002] The specific published documents cited by the author in this application file are concentrated at the end of this specification. [0003] The quotation of prior art in this specification should not be regarded as an admission or in any form implying that the prior art constitutes a part of common general knowledge in any country. [0004] Hepatitis C virus (HCV) is a major public health problem, with an estimated 123 million chronically infected people worldwide. There is no vaccine or post-exposure prevention method available. The currently available treatment methods are limited to the administration of ribavirin and pegylated interferon, which show a limited efficacy of 40-80% and cause serious side effects. HCV is the only member of Hepacivirus in the Flaviviridae family (Flaviviridae) and is divided into 6 ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/29C12N7/00C07K14/02C12Q1/70
CPCA61K39/12G01N33/56983C12N7/00C07K14/1833C07K2317/76C07K16/109C12N2770/24222C12N2770/24262C12N2770/24261C07K14/005A61K39/00
Inventor 海蒂·卓默尔潘提利斯·庞博瑞斯凯萨琳·麦卡弗里
Owner THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD